Excipient

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Retrieved on: 
onsdag, mars 13, 2024

Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.

Key Points: 
  • Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.
  • In NHP studies when administered intravenously at clinically relevant doses, STAC-BBB demonstrated its potential to be a leading neurotropic capsid.
  • Exhibited 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published neurotropic capsid variants evaluated in the study.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.

IFF Brings Science-Backed Excipients to Asia Pharmaceutical Industry at CPhI Japan 2024

Retrieved on: 
tisdag, mars 26, 2024

TOKYO, March 25, 2024 /PRNewswire/ -- IFF, a global leader in food and beverage, home and personal care and health, will present its broad portfolio and latest excipient technology to CPhI Japan 2024 at booth 5K21, Tokyo Big Sight, Tokyo from April 17-19.IFF's Pharma Solutions offers high-quality pharmaceutical solutions backed by extensive research and expertise. The team will showcase its comprehensive cellulosic-derived excipients portfolio of innovative solutions, from binders and disintegrants to lubricants and matrix systems across the immediate release, controlled release, pediatric and novel delivery formulations.

Key Points: 
  • IFF's Pharma Solutions offers high-quality pharmaceutical solutions backed by extensive research and expertise.
  • "As a first-time participant at CPhI Japan, we are excited about the opportunity to connect with customers and industry peers," said Frank Zhao, commercial leader, Asia-Pacific, Pharma Solutions, IFF.
  • "This event provides us with a valuable opportunity to showcase our innovative offerings and demonstrate our commitment to driving advancements in pharmaceutical development."
  • IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by IFF or affiliates of IFF unless otherwise noted.

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
måndag, mars 25, 2024

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
måndag, mars 25, 2024

"Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"

Key Points: 
  • "Global Growth Trends in Clinical Trial Supply & Logistics: Navigating Challenges, Driving Innovation"
    Clinical trial supply and logistics (CTSL) is a critical backbone for conducting clinical studies worldwide, providing essential services, including planning, storing, managing, and distributing clinical trial materials (CTMs).
  • South America also sees increased adoption of clinical trial supply and logistics, fueled by its developing healthcare infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trial Supply & Logistics Market.
  • "Dive into the Clinical Trial Supply & Logistics Market Landscape: Explore 187 Pages of Insights, 582 Tables, and 26 Figures"

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

Retrieved on: 
måndag, februari 26, 2024

PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.)

Key Points: 
  • PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.)
  • product for commercial launch in March 2024.
  • Additionally, the Company is in advanced stages of development and testing of 9 other skincare products anticipated to launch over Spring and Summer 2024.
  • The Carmell skincare product portfolio:
    Carmell G.L.E.E.

Compilation of quality review of documents (QRD) on stylistic matters in product information

Retrieved on: 
söndag, mars 10, 2024

29 February 2024

Key Points: 
    • 29 February 2024
      EMA/25090/2002 rev.23*
      Human Medicines Division

      Compilation of QRD decisions on stylistic matters in product information
      Issues
      Abbreviations

      Connected problems
      Subscript and superscript

      QRD Suggestions
      Acronyms must be written in their standard form; e.g.

    • Cmax, Cmax
      Abbreviations and

      Not always understood,

      Non-standard abbreviations and acronyms should be avoided, and the term should be written out in full.

    • The same applies when stating the pharmaceutical form in section 3 of the SmPC and section 4 of the labelling;
      i.e.
    • critical steps prior to administration of the product should also be included (section 5 of Annex IIIA).
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 2/23

      Issues

      Connected problems

      QRD Suggestions

      emphasise in the labelling
      the special handling prior
      to administration of the
      product.

    • Consistency

      Inconsistencies in style are

      Once a particular style or house style has been selected, it must be used consistently throughout the text.

    • Tradename 150 mg solution for injection in pre-filled syringe
      Tradename 150 mg solution for injection in pre-filled pen

      information annexes?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 3/23

      Issues
      Desiccant

      Connected problems

      QRD Suggestions

      For medicinal products

      The foil of blister packs containing a desiccant must be clearly labelled to show which blister pocket contains

      packaged with a desiccant

      the desiccant.

    • For bottles containing a desiccant, a similar statement should also be considered provided there

      mistake the desiccant for a

      is available space.

    • It can only be included in brackets in section 3 of the

      where can this be

      SmPC and section 4 of the labelling.

    • Direct speech should only
      be used in section 6 of the SmPC for instructions about shelf-life, storage, handling and disposal.
    • The term ?drug? though can be used in the product information annexes when it is part of a standard set of
      terms (e.g.
    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 5/23

      Issues
      Foreign terms

      Connected problems

      QRD Suggestions

      Foreign terms, particularly

      Foreign terms must be written in italics; e.g.

    • Patients can be referred to as ?he? or

      physician is often referred

      as ?she? when the medicinal product is exclusively for use by males or females.

    • if the product in question might be

      measurements are

      used by elderly patients), in brackets after the metric measures in the English text.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 6/23

      Issues

      Connected problems

      QRD Suggestions

      product name is composed
      of MAH+INN?

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 7/23

      Issues

      Connected problems

      QRD Suggestions
      MT: English
      BG: Bulgarian
      NL: Dutch
      CZ: Czech or English at applicant?s discretion.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 14/23

      Issues

      Connected problems

      QRD Suggestions
      considered, e.g.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 16/23

      Issues
      Symbols: Non-Unicode

      Connected problems

      QRD Suggestions

      The use of non-Unicode

      Only Unicode symbols must be used in submitted product information annexes.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 20/23

      Issues

      Connected problems

      Units: SI base units -

      International Standard

      litre

      base units have been
      introduced in the European
      Union with Council
      Directive 80/181/EEC of
      20.12.79 (O.J.

    • Compilation of QRD decisions on stylistic matters in product information
      EMA/25090/2002

      Page 23/23

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings

Retrieved on: 
onsdag, februari 21, 2024

DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced a poster presentation of findings from a systematic literature review and meta-analysis of the safety, efficacy, and real-world outcomes of extracorporeal photopheresis (ECP) treatment for patients with steroid-refractory chronic graft-versus-host disease (SR-cGvHD).1 An analysis of 47 studies reporting on the THERAKOS™ CELLEX™ Photopheresis System showed that treatment of SR-cGvHD with ECP was associated with improvements in patients' overall survival (OS), failure-free survival (FFS), and overall response rate (ORR).1 The results will be shared in a poster presentation at the 2024 Tandem Meetings, the combined Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 21-24, 2024 in San Antonio, TX.

Key Points: 
  • Skin-specific response at Months 2-3 and at Months 4-6 were 34.86% (95% CI: 13.26-65.21) and 54.22% (95% CI: 35.67-71.67), respectively.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to THERAKOS ECP.
  • THERAKOS™ Photopheresis is contraindicated in:
    THERAKOS™ Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available.
  • Please refer to the THERAKOS™ CELLEX™ Photopheresis System Operator Manual for a complete list of warnings and precautions and adverse events.

A patch a day? Why the vitamin skin patches spruiked on social media might not be for you

Retrieved on: 
tisdag, februari 13, 2024

Vitamin patches are trending on social media and advertised in posts and podcasts.

Key Points: 
  • Vitamin patches are trending on social media and advertised in posts and podcasts.
  • With patches marketed for sleep, detox, immunity and hangovers, they are being talked up as near magical fix-all stickers.

What are vitamin patches?

  • Vitamin patches are adhesives designed to deliver vitamins or nutrients to your bloodstream directly through the skin.
  • Patches promising an energy boost offer caffeine, taurine, gluconolactone, green tea extract and vitamins B3, B5 and B6.

Do they work and are they safe?

  • Vitamins are generally approved as listed medicines, meaning the ingredients have been assessed for safety but not for efficacy (whether they do what they promise).
  • However, there are no items listed as vitamin patches on the Australian Register of Therapeutic Goods.
  • Ordinarily, to be absorbed through the skin a chemical needs to be lipophilic, meaning it likes fats and oils more than water.
  • So, the form in which the vitamins have been produced and supplied will dictate whether they will get into the skin.
  • The health condition called scurvy is thought to occur when daily vitamin C intake drops lower than 7 milligrams per day.
  • The recommended daily intake of vitamin C is around 45 milligrams per day – more if a woman is breastfeeding.


Read more:
Is TikTok right – will eating three carrots a day really give me a natural tan?

Why not just take a tablet?

  • One selling point used by the marketers is that patches are a “cleaner” form of vitamins.
  • A vitamin in tablet or gummy form will contain inactive ingredients called excipients.
  • But many patches don’t list all their ingredients – just the active vitamins – so this claim can not be tested.

Should you buy them?


As there are no vitamin patches approved by the TGA in Australia, you should not buy them. If at some point in the future they become listed medicines, it will be important to remember that they may not have been assessed for efficacy. If you remain curious about vitamin patches, you should discuss them with your doctor or local pharmacist.

  • He is a Fellow of the Royal Australian Chemical Institute, a member of the Australasian Pharmaceutical Science Association, and a member of the Australian Institute of Company Directors.
  • Nial regularly consults to industry on issues to do with medicine risk assessments, manufacturing, design, and testing.

Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd's Commercial Launch of VIVJOA® (Oteseconazole) Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China

Retrieved on: 
onsdag, februari 7, 2024

DURHAM, N.C., Feb. 7, 2024 /PRNewswire/ -- Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") has commercially launched VIVJOA® (oteseconazole) in China, making available an innovative oral azole antifungal indicated for the treatment of severe vulvovaginal candidiasis (VVC). VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.

Key Points: 
  • VIVJOA is contraindicated for females of reproductive potential, pregnant and lactating women, and patients with known hypersensitivity to active ingredients, excipients, and azoles.
  • "The disease burden in China is significant, and access to VIVJOA provides health care providers and women suffering with severe VVC a new treatment option."
  • Vulvovaginal candidiasis is an exceedingly common mucosal infection usually caused by Candida albicans but can occasionally be caused by other Candida species or yeasts.
  • In April 2022, the U.S. Food and Drug Administration (FDA) approved VIVJOA (oteseconazole) Capsules as the first medication for Recurrent Vulvovaginal Candidiasis (RVVC, or chronic yeast infection).

Bruker Acquires Nanophoton Corporation, a Japanese Technology Leader in Research Raman Microscopy with 20 Years of Experience

Retrieved on: 
onsdag, februari 7, 2024

Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation , a pioneer focused on advanced research Raman microscopy systems.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation , a pioneer focused on advanced research Raman microscopy systems.
  • Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced Raman microscopes, serving academic and industrial research customers, primarily in Japan.
  • This acquisition fills a gap in Bruker’s molecular microscopy portfolio, and Bruker is looking forward to offering fast, flexible and sensitive Nanophoton Raman microscopy systems worldwide for research and development in the life sciences, biopharma, advanced materials, semiconductors and polymers.
  • We are look forward to this new opportunity to bring the differentiated Nanophoton Raman imaging systems to our research customers worldwide with global support.”
    Financial terms of the transaction were not disclosed.